Momentum Stocks Try To Beat Analysts’ Views: Annaly Capital Management (NYSE:NLY), Synchrony Financial (NYSE:SYF)

Annaly Capital Management, Inc. (NYSE:NLY) [Trend Analysis] luring active investment momentum, shares a decrease -1.13% to $10.46. Finally to see some strong financial remarks by WSJ over NLY performance. Out of the pool of analysts 1 gave their BUY ratings on the stock in previous month as 1 analyst having BUY in current month. The stock was ranked as Underweight by 1 analyst while 1 analyst gave SELL rank. Majority ranked Hold from the pool of analysts.

The next year first quarter EPS estimates trend for current period shows $0.29 while one month ago this estimate trend was for $0.29. EPS indicator shows the robustness of the stock and its analysis opens up the clear picture of company’s profitability. On annual basis of EPS, FY 2017 Estimate Trends at current were for $1.14 and for the one month was for $1.15 as compared to three months ago was for $1.15. Whereas, NLY received highest price target of 11 and low target of 9. The stock price target chart showed average price target of 10.22 as compared to current price of 10.80.

The total volume of 6.46 Million shares held in the session was surprisingly higher than its average volume of 6793.47 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 143.20%, and looking further price to next year’s EPS is -1.71%. While take a short look on price to sales ratio, that was 10.38 and price to earnings ratio of 90.17 attracting passive investors.

Several matter pinch shares of Synchrony Financial (NYSE:SYF) [Trend Analysis], as shares moving up 1.83% to $37.32 with a share volume of 4.61 Million. Finally, analysts shed their light over the SYF price targets; maintaining price high target of 49 while at average the price target was 42.39 in contrast with the current price of 36.85. The price targets are usually acts as the boosters or blasters in the performance of stock. A higher price target would definitely provide confidence to investors during the trading action, consideration given by Wall Street Journal.

So does the rankings given by analysts; let us highlight rankings table and we had 19 analysts recommending BUY ratings for current month and for previous month 19 stands on similar situation; while 3 for the current month as compared to 3 analysts recommending for HOLD from the pool for previous month. While 2 stands at overweight. For the overall, consensus ratings were for Buy. The stock is going forward its 52-week low with 62.60% and moving down from its 52-week high price with -1.58%. The float short ratio was 1.04%, as compared to sentiment indicator; Short Ratio was 1.35.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *